Showing results (341-350 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|June 2, 2012
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?Zachary S Zumsteg, Michael J Zelefsky
The Lancet. Oncology|June 2, 2012
Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomyKaren E Hoffman, Elizabeth A Mittendorf, Thomas A Buchholz
The Lancet. Oncology|May 22, 2012
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trialsDiether Lambrechts, Bart Claes, Paul Delmar, et al.
The Lancet. Oncology|August 17, 2013
Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysisNicole Skoetz, Sven Trelle, Michaela Rancea, et al.
The Lancet. Oncology|August 13, 2013
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialDavid Cameron, Julia Brown, Rebecca Dent, et al.
The Lancet. Oncology|September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.
The Lancet. Oncology|October 4, 2011
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trialAmrita Krishnan, Marcelo C Pasquini, Brent Logan, et al.
The Lancet. Oncology|August 23, 2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trialHagop M Kantarjian, Andreas Hochhaus, Giuseppe Saglio, et al.
The Lancet. Oncology|October 15, 2011
Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort studyPer-Henrik Zahl, Peter C Gøtzsche, Jan Mæhlen
The Lancet. Oncology|October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Pageof 336